Constellation Pharmaceuticals (CNST) Posts Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Constellation Pharmaceuticals (NASDAQ:CNST) released its earnings results on Thursday. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.14), Fidelity Earnings reports.

Constellation Pharmaceuticals stock traded down $0.23 during trading on Friday, reaching $5.86. 6,229 shares of the company were exchanged, compared to its average volume of 19,381. Constellation Pharmaceuticals has a 52-week low of $5.57 and a 52-week high of $12.21.

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on Constellation Pharmaceuticals in a research report on Monday, August 13th. They issued an “overweight” rating and a $17.00 target price on the stock. Oppenheimer assumed coverage on Constellation Pharmaceuticals in a research report on Monday, August 13th. They issued an “outperform” rating and a $21.00 target price on the stock. BMO Capital Markets assumed coverage on Constellation Pharmaceuticals in a research report on Monday, August 13th. They set an “outperform” rating and a $19.00 price objective on the stock. Cann assumed coverage on Constellation Pharmaceuticals in a research report on Monday, August 13th. They set an “outperform” rating and a $21.00 price objective on the stock. Finally, Zacks Investment Research upgraded Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a research report on Monday, October 15th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $17.15.

TRADEMARK VIOLATION NOTICE: “Constellation Pharmaceuticals (CNST) Posts Quarterly Earnings Results, Misses Estimates By $0.14 EPS” was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2018/11/10/constellation-pharmaceuticals-cnst-posts-quarterly-earnings-results-misses-estimates-by-0-14-eps.html.

Constellation Pharmaceuticals Company Profile

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.

See Also: Diversification

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply